CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

CRISPR Therapeutics has a 12-month low of $30.96 and a 12-month high of $67.88. CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th.

Norges Bank acquired a new position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the fourth quarter, according to its most recent filing with the SEC.The firm acquired 443,536 ...

April 8, 2025 /PRNewswire/ -- Synthego and Vita Therapeutics, Inc. today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into Vita's cell therapeutic ...

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR ...

Bayer is to set up a joint venture with CRISPR Therapeutics and acquire a minority stake in the firm, one of the pioneers in the potentially revolutionary gene-editing technology. The partnership ...

and human therapeutics. Growing investments in biotechnology research and development, coupled with increased funding from public and private sectors, are accelerating the adoption of CRISPR across ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...